Early screening of a drug candidate's potential to induce or inhibit CYP2B6 is a critical step in the drug development process. Cayman's CYP2B6 Induction STEP Reporter Assay Kit (Luminescence) is a novel method to evaluate human Constitutive Androstane Receptor 3 (hCAR3)-mediated CYP2B6 induction for the discovery of hepatic CYP inducers. STEP (Surface Transfection and Expression Protocol) is a patented, solid phase transient transfection technology that overcomes many of the disadvantages of other transfection approaches. Cayman's assay consists of a 96-well plate coated with a STEP complex containing a Secreted Alkaline Phosphatase (SEAP) reporter regulated by the human CYP2B6 gene promoter. The STEP complex also contains two nuclear expression constructs, hCAR3 and human Hepatocyte Nuclear Factor-4(alpha) (HNF-4(alpha)). Cells grown on the CYP2B6 STEP strip plate will introduce the reporter gene and express CAR3 and HNF-4(alpha). Binding of inducer-activated transcription factors to the CYP2B6 promoter initiates expression of SEAP, which is secreted into the cell culture medium. Aliquots of medium are removed at fixed time intervals and SEAP activity is measured by adding a luminescence-based alkaline phosphatase substrate provided in the kit. The kit is simple to use and can be easily adapted to high-throughput screening for potential CAR-mediated CYP2B6 inducers. A known CYP2B6 inducer, CITCO, is included in the kit for use as a positive control.